ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1494

Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Abstract Number: 1769

Patient-reported COVID-19 Infection in Pregnant Women with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey
Abstract Number: 0159

Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Abstract Number: 1866

Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas 2017
Abstract Number: 0169

Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Abstract Number: 0526

Patient-Reported Outcomes in Antiphospholipid Syndrome
Abstract Number: 1081

Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
Abstract Number: 1241

Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Abstract Number: 1210

Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Abstract Number: 1728

Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Abstract Number: 0011

Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
Abstract Number: 1248

Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort
Abstract Number: 0193

Patients with Asthma Have a Higher Risk of Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Abstract Number: 1739

Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Abstract Number: 1981

Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].